How to Diagnose Cannabinoid Hyperemesis Syndrome
Diagnose CHS using three clinical criteria: (1) stereotypical episodic vomiting occurring 3+ times annually, (2) chronic cannabis use for >1 year with frequency >4 times per week, and (3) symptom resolution after 6 months of cannabis abstinence or duration equal to 3 typical vomiting cycles. 1
Clinical Diagnostic Approach
The 2024 AGA Clinical Practice Update provides the most current diagnostic framework for CHS 1. The diagnosis is primarily clinical and based on pattern recognition rather than laboratory or imaging findings.
Essential Diagnostic Criteria
Three mandatory elements must be present:
Clinical Features
- Stereotypical episodic vomiting resembling cyclic vomiting syndrome
- Episodes occur 3 or more times annually
- Cyclic pattern with symptom-free intervals between episodes
Cannabis Use Pattern
- Duration: Cannabis use for more than 1 year before symptom onset
- Frequency: Average use more than 4 times per week
- Typically daily use (68% of cases) 1
Cannabis Cessation Response
- Complete resolution of symptoms after at least 6 months of cannabis abstinence
- OR symptom resolution for duration equal to 3 typical vomiting cycles in that patient
- This criterion may require prospective confirmation 1
Supportive Clinical Features
Hot water bathing behavior is reported in 71% of CHS cases and serves as a strong clinical indicator, though it is not pathognomonic since it also occurs in cyclic vomiting syndrome 1. Patients compulsively take prolonged hot showers or baths for symptom relief.
Typical demographics:
- Mean age: 30 years
- Male predominance: 69%
- Mean duration of cannabis use before symptom onset: 6.6 years 1
Critical Differential Diagnosis
In the emergency department setting, you must first exclude life-threatening conditions 1:
- Acute abdomen
- Bowel obstruction
- Mesenteric ischemia
- Pancreatitis
- Myocardial infarction
In the outpatient setting, after excluding structural abnormalities through appropriate imaging, consider 1:
- Cyclic vomiting syndrome (CVS) - the primary differential
- Gastroparesis
- Rumination syndrome
- Pregnancy-related nausea/vomiting
- Migraine-associated vomiting
- Functional chronic nausea and vomiting syndrome
Practical Diagnostic Pitfalls
The major diagnostic challenge is that CHS is frequently misdiagnosed, resulting in extensive unnecessary investigations and diagnostic delays averaging 3-6 years 2. Many patients undergo repeated emergency department visits and invasive testing before diagnosis 3.
Cannabis cessation requirement for diagnosis: Recent evidence emphasizes that counseling must specify a minimum of 3 months of complete cannabis cessation to achieve symptom relief and confirm diagnosis 4. This is longer than many clinicians initially recommend and explains why some patients relapse when they resume cannabis use too early.
Patient awareness barrier: Despite recurrent vomiting episodes and CHS diagnosis, many patients remain uncertain about the role of cannabis and attribute symptoms to food or other causes 1. Direct, explicit counseling about the causal relationship is essential.
Symptom Pattern Recognition
Prodromal phase symptoms cluster in the morning (63.1% of cases) with predominant complaints of nausea and stomach pain 5. Women report more frequent and prolonged symptoms than men 5.
Cannabis use patterns associated with CHS:
- 96.5% used cannabis at least daily
- 45% used 6+ times per day around symptom onset
- Smoking flower and vape cartridges most commonly reported
- Vape cartridge use associated with shorter time to symptom development 5
Rome IV Classification
CHS is formally classified as a disorder of gut-brain interaction in the Rome IV criteria for functional gastrointestinal disorders since 2016 1. This classification supports the clinical diagnosis when structural causes have been excluded.
Key diagnostic principle: Suspect CHS in any patient with chronic nausea and vomiting who uses cannabis 1. The diagnosis requires high clinical suspicion, detailed cannabis use history, and willingness to pursue a therapeutic trial of complete cannabis cessation as both treatment and diagnostic confirmation.